UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $833,000 Stake in Liquidia Co. (NASDAQ:LQDA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in shares of Liquidia Co. (NASDAQ:LQDA) by 5.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 83,289 shares of the company’s stock after selling 4,361 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.11% of Liquidia worth $833,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in LQDA. Charles Schwab Investment Management Inc. boosted its position in Liquidia by 144.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after purchasing an additional 230,820 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Liquidia by 18.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock worth $2,496,000 after buying an additional 32,076 shares during the period. BNP Paribas Financial Markets grew its stake in Liquidia by 735.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after buying an additional 123,402 shares during the last quarter. Sapient Capital LLC bought a new position in Liquidia in the 3rd quarter valued at about $1,336,000. Finally, HighVista Strategies LLC acquired a new stake in Liquidia during the second quarter worth approximately $1,461,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Stock Performance

LQDA opened at $10.59 on Friday. Liquidia Co. has a 52-week low of $7.76 and a 52-week high of $16.99. The firm has a market cap of $896.31 million, a P/E ratio of -6.50 and a beta of 0.22. The business’s fifty day moving average is $10.91 and its 200-day moving average is $11.20.

Analyst Ratings Changes

Several research firms have recently commented on LQDA. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Scotiabank started coverage on Liquidia in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price for the company. Finally, Lifesci Capital assumed coverage on shares of Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Insiders Place Their Bets

In other Liquidia news, insider Rajeev Saggar sold 2,260 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now directly owns 207,383 shares in the company, valued at $2,304,025.13. This represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Roger Jeffs sold 8,053 shares of Liquidia stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $89,468.83. Following the completion of the transaction, the chief executive officer now owns 812,193 shares in the company, valued at approximately $9,023,464.23. The trade was a 0.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,007 shares of company stock worth $245,780 over the last ninety days. Corporate insiders own 30.10% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).